CellOrigin announced treatment of the first patient with CAR-M in China and reported the second generation of CAR-M for solid tumors
HANGZHOU, China, Dec. 20, 2023 /PRNewswire/ -- Recently, a CAR-macrophage therapy product (CAR-M) SY001 from CellOrigin Biotechnology (Hangzhou) C...
Yaoyao Li Zhejiang University Cellorigin Biotechnology Hangzhou Co Ltd Wang Ben Research Group Of Zhejiang University Proceedings Of The National Academy Sciences Cellorigin Biotechnology
Source: businessinsider.com